文献速递肝病

基于新型机器学习混杂校正方法的活体肝移植个体化生存获益估计

Personalized survival benefit estimation from living donor liver transplantation with a novel machine learning method for confounding adjustment.
PubMed 文献 · J Hepatol · 2025-05-28

本研究利用美国器官共享联合网络数据库2002至2023年72581例成人肝移植受者数据,开发决策路径相似匹配(DPSM)机器学习算法模拟随机对照试验条件。匹配后活体肝移植较尸体肝移植的预测10年平均生存获益为10.3%(SD=5.7%),在原发性硬化性胆管炎和丙型肝炎中获益最大。

要点

  • DPSM匹配后AUROC从0.82降至0.51,有效减少混杂关联。
  • 随机生存森林模型C指数优于Cox回归:活体肝移植0.67 vs 0.57,尸体肝移植0.74 vs 0.65。
  • 活体肝移植较尸体肝移植的预测10年生存获益为10.3%(SD=5.7%),原发性硬化性胆管炎为12.4%±5.3%,丙型肝炎为12.1%±4.7%。

核心结论

  • DPSM为观察性数据提供了一种模拟随机对照试验条件的新型机器学习方法,可在减少混杂的同时实现个体化生存预测。
  • 该方法为临床医生更自信地评估治疗效果提供了新工具。

研究设计与样本

  • 回顾性研究,使用器官共享联合网络数据库2002至2023年成人(≥18岁)肝移植候选人数据。
  • 共纳入72581例肝移植受者,其中93.8%接受尸体肝移植,6.2%接受活体肝移植。
  • 训练随机森林分类器以临床人口学特征预测移植类型,经超参数调优后提取个体决策路径并计算活体-尸体肝移植决策路径对的树平均汉明距离(dh),通过最小化总dh进行一对一匹配。
  • 在匹配队列上训练随机生存森林模型预测移植后生存。

主要发现

  • 匹配后AUROC从0.82降至0.51,表明DPSM成功减少了混杂关联。
  • 随机生存森林模型在两组均优于传统Cox回归:活体肝移植C指数0.67 vs 0.57,尸体肝移植C指数0.74 vs 0.65。
  • 活体肝移植较尸体肝移植的预测10年平均生存获益为10.3%(SD=5.7%)。
  • 活体肝移植生存获益在原发性硬化性胆管炎(12.4%±5.3%)和丙型肝炎(12.1%±4.7%)中最大。

关键数值与推荐

  • 原文未报告推荐条款。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Addressing many clinical questions, such as estimating survival differences between living donor (LDLT) and deceased donor liver transplantation (DDLT), relies on observational studies, as randomized-controlled trials (RCTs) are often unfeasible. Thus, we developed decision path similarity matching (DPSM) - a novel machine learning (ML)-based algorithm that simulates RCT-like conditions to mitigate confounding in observational data. METHODS: We conducted a retrospective study of adult (≥18-years-old) LT candidates between 2002-2023 using the Scientific Registry of Transplant Recipients database. A random forest classifier was trained to predict transplant type from clinicodemographic characteristics. After hyperparameter tuning, decision paths were extracted for individual patients and tree-averaged Hamming distances (dh) were computed for every LDLT-DDLT decision path pair. One-to-one matching was performed by minimizing the total dh across all patient pairs. Random survival forest models were then trained on the matched cohorts to predict post-transplant survival. RESULTS: Of 72,581 LT recipients, 93.8% underwent DDLT and 6.2% underwent LDLT. After matching LDLT with DDLT recipients, DPSM successfully reduced confounding associations as shown by a decrease in AUROCpost-match from 0.82 to 0.51. Random survival forest models outperformed traditional Cox regression in both groups (C-indexldlt 0.67 vs. 0.57; C-indexddlt 0.74 vs. 0.65). The predicted 10-year mean survival gain for LDLT over DDLT was 10.3% (SD = 5.7%). In particular, the survival benefit from LDLT was greatest for primary sclerosing cholangitis (12.4% ± 5.3%) and HCV (12.1% ± 4.7%) compared to other etiologies. CONCLUSIONS: DPSM offers a novel ML-based method for simulating RCT-like conditions in observational data, enabling personalized survival prediction while minimizing confounding. This approach equips clinicians with a new tool to more confidently evaluate treatment effects. IMPACT AND IMPLICATIONS: Living donor liver transplantation (LDLT) has emerged as an effective strategy to expand the donor pool, though data from randomized-controlled trials (RCTs) are lacking due to ethical and practical barriers. We developed a novel machine learning-based algorithm termed decision path similarity matching (DPSM), which more effectively reduces bias in observational data by creating cohorts that better approximate those in RCTs. Using DPSM, LDLT was associated with a predicted 10-year mean survival gain of 10.3% (SD = 5.7%) over deceased donor liver transplantation. LDLT was also shown to be particularly beneficial for certain etiologies, i.e. HCV and PSC. DPSM provides clinicians with a powerful tool that transforms real-world observational data into an RCT-like framework, making it an invaluable method in situations where true randomization is not feasible.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Gangadhar A, Hasjim BJ, Zhao X, et al. Personalized survival benefit estimation from living donor liver transplantation with a novel machine learning method for confounding adjustment. J Hepatol. 2025. PMID: 40446930. doi:10.1016/j.jhep.2025.04.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。